Home Featured Page 232

Featured

Latest

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

atai Life Sciences announces the launch of PsyProtix, to develop a...

PTSF80 – Decriminalization in Seattle, San Pedro, and The Dark Web

Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary...

Psygen Announces use of Psilocybin in Human Trial and Provides Update...

Mydecine Completes Spin-Out of U.S. Cannabis Assets

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment...

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by...

Psychedelics and Perception Part 2: The First Era of Research

EDITOR PICKS

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

atai Life Sciences announces the launch of PsyProtix, to develop a...

PTSF80 – Decriminalization in Seattle, San Pedro, and The Dark Web

Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary...

Psygen Announces use of Psilocybin in Human Trial and Provides Update...

Mydecine Completes Spin-Out of U.S. Cannabis Assets

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment...

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by...

Psychedelics and Perception Part 2: The First Era of Research

EDITOR PICKS

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY